Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
AssigneesaTyr Pharma, Inc., Pangu BioPharma Limited
InventorsJie Zhou, Ching Fun Lau, Zhiwen Xu, Wing Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
Life of this patent
Estimating the term…
Abstract
Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Claims39
An isolated histidyl-tRNA synthetase (HRS) splice variant polypeptide, for use in a method of reducing inflammatory activity wherein the HRS polypeptide is 50-175 amino acids in length and comprises at least 50 contiguous amino acids of SEQ ID NO:
- 6, or a variant thereof having at least 95% sequence identity to SEQ ID NO:
- 6, where the HRS polypeptide comprises a WHEP domain and lacks a functional aminoacylation domain.
An isolated histidyl-tRNA synthetase (HRS) splice variant polypeptide, for use in a method of reducing inflammatory activity wherein the HRS polypeptide comprises the amino acid sequence of SEQ ID NO:
- 11, or a variant thereof having at least 95% sequence identity to SEQ ID NO:
- 11, where the HRS polypeptide comprises a WHEP domain and lacks a functional aminoacylation domain.
An isolated recombinant histidyl-tRNA synthetase (HRS) for use in a method of reducing inflammatory activity wherein the HRS polypeptide consists essentially of the amino acid sequence of SEQ ID NO:
- 6, 9 or 11.
An isolated recombinant histidyl-tRNA synthetase (HRS) polypeptide, for use in a method of reducing inflammatory activity wherein the HRS polypeptide is 50-175 amino acids in length and comprises at least 50 contiguous amino acids of SEQ ID NO:
- 6, or a variant thereof having at least 95% sequence identity to SEQ ID NO:
- 6, where the HRS polypeptide comprises a WHEP domain and lacks a functional aminoacylation domain.
Dependencies are inferred from the claim text.